Three London stocks are on the march and are expected to rise by more than 50% over the next 12 months. CNBC Pro screened for stocks covered by analysts at RBC Capital Markets that have risen this year, have momentum behind them, and have an upside potential of more than 50%. Team17 Shares of Team17 , an England-based video game publisher, could rise by 51.6% to £3.60 ($4.68) over the next 12 months, according to RBC. British stocks are priced in pence. One hundred pence amounts to one British pound. Team17 says it publishes “indie games developed by independent developers.” RBC Capital Markets began coverage of the stock in July, citing a “premium” management team at the helm at Team17, a new strategy and acquisitions as a key driver of growth. “With a combination of founder Debbie Bestwick’s indie expertise, new CEO Steve Bell’s refreshed strategy and clear messaging and new Chair Frank Sagnier’s experience in both franchise building and M & A, we believe the group is well positioned to drive both organic and inorganic growth,” said RBC analyst Ross Broadfoot in a note to clients on July 15. TM17-GB 1Y line More recently, RBC said the company reported “a good set of results” in September. The company reported £80.6 million in total sales, missing revenue expectations of £81.5 million marginally. Net profit came in much higher than expected at £19.2 million. “The share price has been weak in recent times suggesting a warning, perhaps driven by the expected weaker new title performance. The group is making good strides against its strategy in terms of cost control and growth in 1st party IP with 150bps of margin accretion at the [adjusted earnings] level,” Broadfoot added. Broadfoot has a success rate of 75%, according to TipRanks. This means that three out of four ratings the analyst made over the past year made a profit for investors. Team17 has a median price target of £3.60, indicating a 51.6% upside. The stock is up 28% this year, Drax Group Shares of Drax , one of the U.K.’s largest power plant operators, could soar over the next year by 65%, according to a forecast by RBC Capital Markets. In July, the company announced a £300 million share buyback program, which amounted to nearly 15% of the company’s market cap at the time. Subsequently, the stock has risen by almost 20% since. RBC’s Alexander Wheeler said the investment bank was “positive on the growth in the core business” at Drax, which primarily burns wood pallets to generate electricity. Wheeler also noted that the stock had “significant upside potential” after the company reported its first-half results on July 26. Oxford Biomedica Shares of Oxford Biomedica can double despite having risen by more than 70% this year already, according to RBC. The investment bank has the most bullish view among seven analysts covering the stock. The company, spun out of the University of Oxford, specializes in gene and cell therapy. RBC analyst Charles Weston said the stock remains “materially undervalued” after the company reported its first half-year financial results. OXB said sales for the first half of 2024 were up 18% to £51.8 million compared to last year. RBC also said the stock could rise by 387% over the next three years as the company turns profitable. “As OXB should turn meaningfully profitable in 2026 and could reach more of a peak margin in 2028, we apply a 20x EV/[adjusted profit] (a slight premium to peers to reflect OXB’s higher expected growth) to our estimate of 2028E [adjusted profit] for an implied end-2027 fair value of £18,” Wheeler said in a note to clients on Sept 23.